|
|
|
|
LEADER |
00000cam a2200000 a 4500 |
001 |
SCIDIR_on1052447433 |
003 |
OCoLC |
005 |
20231120010313.0 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
180913s2018 enk o 000 0 eng d |
040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d N$T
|d NLE
|d OPELS
|d OCLCF
|d MERER
|d UKMGB
|d OTZ
|d OCLCQ
|d LVT
|d ITD
|d D6H
|d EBLCP
|d OCLCQ
|d S2H
|d OCLCO
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d SFB
|d OCLCQ
|d OCLCO
|
015 |
|
|
|a GBB8H4149
|2 bnb
|
016 |
7 |
|
|a 019047539
|2 Uk
|
019 |
|
|
|a 1053787059
|a 1053844733
|a 1229532973
|
020 |
|
|
|a 9780128119211
|q (electronic bk.)
|
020 |
|
|
|a 0128119217
|q (electronic bk.)
|
020 |
|
|
|z 9780128119204
|
020 |
|
|
|z 0128119209
|
035 |
|
|
|a (OCoLC)1052447433
|z (OCoLC)1053787059
|z (OCoLC)1053844733
|z (OCoLC)1229532973
|
050 |
|
4 |
|a QH588.S83
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
072 |
|
7 |
|a MQW
|2 bicssc
|
082 |
0 |
4 |
|a 616.02/774
|2 23
|
245 |
0 |
2 |
|a A roadmap to nonhematopoietic stem cell-based therapeutics :
|b from the bench to the clinic /
|c edited by Xiao-Dong Chen.
|
260 |
|
|
|a London :
|b Academic Press,
|c 2018.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed September 17, 2018)
|
520 |
|
|
|a A Roadmap to Non-hematopoietic Stem Cell-Based Therapeutics: From the Bench to the Clinic is a resource that provides an overview of the principles of stem cell therapy, the promises and challenges of using stem cells for treating various clinical conditions, and future perspectives. The overall goal is to facilitate the translation of basic research on stem cells to clinical applications. The properties of stem cells from various sources are reviewed and the advantages and disadvantages of each for clinical use are discussed. Modifying stem cell properties through preconditioning strategies using physical, chemical, genetic, and molecular manipulation to improve cell survival, increase cell differentiation potential, enhance production of paracrine factors, and facilitate homing to the site of injury or disease upon transplantation are reviewed. Various routes of stem cell administration and dosing, and the duration of effects, are explored. Individual chapters are written by experts in the field and focus on the use of stem cells in treating various degenerative diseases, autoimmune diseases, wound healing, cardiovascular disease, spinal cord injury, oral and dental diseases, and skeletal disorders. Finally, experts in the regulatory arena discuss mechanisms used in different countries for approving the use of stem cells to treat diseases and many common issues that are typically encountered while seeking approval for this class of therapeutic agent.
|
505 |
0 |
|
|a Intro; Title page; Table of Contents; Copyright; List of Contributors; Preface; Part I. Principles & Concepts; Chapter 1. What Can We Learn From This Book?; 1. Introduction; 2. What Can We Learn From Hematopoietic Stem Cell Therapy?; 3. Why Is the Term "Mesenchymal Stem Cells (MSCs)" So Confusing?; 4. What Is the Origin of MSCs?; 5. What Are the Characteristics of a Culture System That Maintains MSC Properties During Expansion?; 6. What Are the Potential Challenges Facing the Development and Translation of MSC-Based Therapies?; 7. What Are the Effects of Government Regulation?; 8. Conclusions.
|
505 |
8 |
|
|a Chapter 2. Features of Mesenchymal Stem Cells1. Introduction; 2. Prospective Isolation of Human BMSC; 3. Perivascular Origin of BMSC; 4. Plasticity of BMSC; 5. Self-Renewal and Growth Potential of BMSC; 6. Immunomodulatory Properties of BMSC; 7. MSC-Like Populations From Other Tissues; 8. iPSC-Derived MSC; 9. Conclusions; List of Acronyms and Abbreviations; Chapter 3. Maintenance and Culture of MSCs; 1. Introduction: Therapeutic Potential of MSCs and Obstacles to Clinical Translation; 2. Why Are Current Culture Systems Unsuitable for MSC-Based Regenerative Medicine?
|
505 |
8 |
|
|a 3. How Must Stem Cell Behavior Be Measured and Analyzed in Order to Develop a More Appropriate Culture System?4. What Is Stem Cell Niche and How Does It Regulate Cell Fate?; 5. Is It Possible to Reconstruct the Stem Cell Niche Ex Vivo?; 6. Does ECM Produced by Stromal Cells Derived From Different Tissues Exhibit a Tissue-Specific Role in Controlling the Fate of MSCs?; 7. Can Stromal Cell-Derived ECMs Be Used to Study the Impact of Aging and Disease-Related Pathologies on the Stem Cell Niche?; 8. Conclusions; List of Abbreviations; Chapter 4. Manufacturing Mesenchymal Stromal Cell Banks.
|
505 |
8 |
|
|a 1. Regulatory Requirements2. Cell Banks; 3. Conclusions; Part II. Promises and Challenges of MSC-Based Therapies; Chapter 5. Mesenchymal Stem Cell-Based Therapy of Osteoarthritis: Current Clinical Developments and Future Therapeutic Strategies; 1. Introduction; 2. Functional Properties of MSCs; 3. Evidence From Preclinical Models That Support a Therapeutic Role for MSCs in OA; 4. Recent Clinical Results of MSC-Based Therapy of OA; 5. Novel Perspectives for Enhancing the Efficacy of MSC Therapy of OA; 6. Conclusions; List of Acronyms and Abbreviations.
|
505 |
8 |
|
|a Chapter 6. Mesenchymal Stem Cell Therapy in Graft Versus Host Disease1. Introduction; 2. Hematopoietic Cell Transplantation; 3. Graft Versus Host Disease; 4. MSC Therapy in GVHD; 5. Future Directions; Chapter 7. Systemic Lupus Erythematosus; 1. SLE Is a Chronic Autoimmune Disease With Challenging Therapies; 2. MSC Deficiency in SLE; 3. Preclinical Study of Allogeneic MSC Therapy in Lupus Models; 4. Clinical Trials of MSC Transplantation in SLE Patients; 5. The Mechanism of Allogeneic MSC Transplantation in Lupus Mice and Humans; 6. Clinical Challenges of Allogeneic MSCT for SLE.
|
650 |
|
0 |
|a Stem cells
|x Therapeutic use.
|
650 |
|
0 |
|a Stem cells
|x Research.
|
650 |
|
6 |
|a Cellules souches
|0 (CaQQLa)201-0058821
|x Emploi en th�erapeutique.
|0 (CaQQLa)201-0373975
|
650 |
|
6 |
|a Cellules souches
|x Recherche.
|0 (CaQQLa)201-0460717
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Stem cells
|x Research
|2 fast
|0 (OCoLC)fst01132977
|
700 |
1 |
|
|a Chen, Xiao Dong,
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Roadmap to nonhematopoietic stem cell-based therapeutics.
|d London : Academic Press, 2018
|z 0128119209
|z 9780128119204
|w (OCoLC)1022773704
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128119204
|z Texto completo
|